Difelikefalin not checked
Vifor Fresenius Medical Care Renal Pharma · Cara Therapeutics, Inc. · MR13A9 · CR845
FollowEvery change as it happens, and a Monday email
Trials
1 active
12 in total · 1 in the EU
What this is
- How it works
- Kappa Opioid Receptor Agonist FDA class
- How it’s given
- “The study includes a screening period of up to 4 weeks (including a 7-day run-in period during the week prior to enrolment), a study treatment period of 12 weeks, and a safety follow-up visit at 7 (up to 10) days after EoT. Total study duration for a single participant is up to 17 to 18 weeks.”In the company’s words, NCT06593392 on ClinicalTrials.gov
- Tested for
- Pruritus, Chronic Kidney Diseases
- Main trialPhase 2
- “Rationale: * People with long term kidney disease who are on haemodialysis (a procedure for removing waste products from the blood) commonly develop a condition that makes their skin very itchy. * Difelikefalin is a medicine that can treat the itching related to long term kidney disease. * Clinical studies have shown difelikefalin to reduce itching in adults on haemodialysis, while being safe and tolerable. * The current study is being done in adolescents aged 12 to 17 years on haemodialysis who have moderate to severe itching related to long term kidney disease to assess if difelikefalin is…”In the company’s words, NCT06593392 on ClinicalTrials.gov
- Other names
- MR13A9 · CR845
Other drugs for Pruritus
- SD-101TriSalus Life Sciences, Inc. · Phase 3
- DupilumabRegeneron · Sanofi · Phase 3
- FexofenadineSanofi · Phase 3
- LinerixibatGSK · Phase 3
- DeucravacitinibBristol Myers Squibb · Phase 3
- RitlecitinibPfizer · Phase 2
Coming up1
- 15 Aug 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 15 Aug 2029 | Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus | |
| Phase 3Completed | 6 Apr 2019 | A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1) | |
| Phase 3Completed | 11 Feb 2020 | Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus | |
| Phase 3Completed | 26 Feb 2020 | CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus | |
| Phase 3Completed | 30 Mar 2020 | CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus | |
| Phase 3Completed | 25 Jan 2022 | A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. | |
| Phase 3Completed | 25 Sep 2024 | Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus | |
| Phase 2Completed | 22 Oct 2019 | A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. | |
| Phase 2Completed | 24 Oct 2019 | A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus | |
| Phase 2Terminated | 29 Jun 2022 | Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus | |
| Phase 1Completed | 11 Jun 2020 | CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients | |
| Phase 1Completed | 9 Oct 2023 | Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026